DCTH Delcath Systems Inc Operating Sales Margin

Public company logo of Delcath Systems, Inc. (DCTH)

Rising sales of the Hepzato system for melanoma treatment are accelerating revenue for Delcath Systems, Inc. (DCTH), driving active momentum in the operating profit margin, which currently stands at approximately 5.20. The business model is based on capturing the liver metastasis targeted therapy niche with high-margin consumables. Structural flexibility is maintained through the complete outsourcing of production and clinical trials to external partners.

DCTH: Delcath Systems Inc Operating Profit Rate 07/04/2022 - 11/19/2026

DCTH (Delcath Systems): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
Fundamental company analysis:DCTH, Delcath Corp
Core merchandise of delcath.com

The metric is calculated as the ratio of operating profit to total revenue. This metric determines cost management efficiency before accounting for financial leverage and tax obligations. For Delcath Systems, Inc. (DCTH), it reflects the oncology team's ability to monetize innovations in medical devices. The efficiency of clinical trials directly impacts the operating result. By analyzing the operating profit margin, an investor assesses the real profitability of the core business.

Competitor analysis

Operating Profitability BeiGene Ltd|Halozyme Therapeutics - Operating Profit Margin|Operating Sales Margin RVMD (Revolution Medicines Corp)|Operating Profit Ratio AAPG|Operating Profitability CG Oncology Therapeutics CGON|Operating Profit Rate URGN|BCAX: Operating Sales Margin|PSNL: Operating Profitability|Erasca (ERAS) - Operating Profitability|Y-mAbs Therapeutics - Operating Profit Rate|AURA (Aura Biosciences Inc) - Operating Margin|Operating Return on Sales candeltx.com CADL|Operating Margin ARAY|SLS (SELLAS Life Sciences Group, Inc.) - Operating Profit Rate|Operating Profitability Actuate Therapeutics, Inc. ACTU|citiusonc.com - Operating Profitability|TuHURA Biosciences Inc. - Operating Margin|TARA - Operating Margin|FATE (Fate Therapeutics) - Operating Sales Margin|Operating Sales Margin Aadi Bioscience, Inc.|Operating Sales Margin TCRX|Operating Profitability CSBR|Operating Margin XBIT|Profitability of Operations CEL-SCI Corp.|Operating Profitability ostherapies.com OSTX|RADX: Return on Sales by Operating Profit|ARTV: Operating Sales Margin|ANL (Adlai Nortye) - Return on Sales by Operating Profit|Veru (VERU) - Operating Profitability|Operating Sales Margin Tempest Therapeutics Inc|Operating Profitability Xilio Therapeutics|Return on Sales by Operating Profit RENB (Renovaro Inc.)|Operating Profitability Mural Oncology PLC (MURA)|Operating Margin Kairos Pharma (KAPA)|Operating Profitability onkuretherapeutics.com OKUR|GDTC: Return on Sales by Operating Profit|CRIS: Operating Sales Margin|apollomicsinc.com (APLM) - Operating Sales Margin|THAR: Operating Margin|Operating Sales Margin Advanced Biomed Inc.|Operating Sales Margin GNPX|Return on Sales by Operating Profit CLDI (Calidi Biotherapeutics)|Operating Margin SBFM|Xenetic Biosciences, Inc. - Return on Sales by Operating Profit|Operating Profitability Salarius Pharmaceuticals SLRX|Operating Margin purple-biotech.com PPBT|AONC - Operating Profitability|BGNE: Operating Profitability|CKPT: Operating Margin|Elevation Oncology - Operating Profit Rate|ICAD (iCAD) - Operating Margin|IKNA: Operating Profit Rate|Operating Profitability Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Operating Profit Rate|Operating Profitability MorphoSys Corporation MOR|NAYA: Return on Sales by Operating Profit|Ascentage Pharma Group International - Operating Margin